AR095593A1 - Agentes quelantes de precursores de producto final de glicación avanzada (age) - Google Patents

Agentes quelantes de precursores de producto final de glicación avanzada (age)

Info

Publication number
AR095593A1
AR095593A1 ARP140101218A ARP140101218A AR095593A1 AR 095593 A1 AR095593 A1 AR 095593A1 AR P140101218 A ARP140101218 A AR P140101218A AR P140101218 A ARP140101218 A AR P140101218A AR 095593 A1 AR095593 A1 AR 095593A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
cooh
integer
formula
Prior art date
Application number
ARP140101218A
Other languages
English (en)
Spanish (es)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR095593A1 publication Critical patent/AR095593A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP140101218A 2013-03-15 2014-03-17 Agentes quelantes de precursores de producto final de glicación avanzada (age) AR095593A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095593A1 true AR095593A1 (es) 2015-10-28

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101218A AR095593A1 (es) 2013-03-15 2014-03-17 Agentes quelantes de precursores de producto final de glicación avanzada (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (enExample)
EP (1) EP2968403A1 (enExample)
JP (4) JP2016512830A (enExample)
KR (1) KR20150130492A (enExample)
CN (1) CN105188718A (enExample)
AR (1) AR095593A1 (enExample)
AU (2) AU2014235500A1 (enExample)
BR (1) BR112015023404A8 (enExample)
CA (1) CA2906501A1 (enExample)
CL (1) CL2015002624A1 (enExample)
CR (1) CR20150545A (enExample)
DO (1) DOP2015000221A (enExample)
EA (1) EA201591733A1 (enExample)
HK (1) HK1220607A1 (enExample)
IL (1) IL241406A0 (enExample)
MA (1) MA38487A1 (enExample)
MX (1) MX2015012843A (enExample)
PE (1) PE20151766A1 (enExample)
PH (1) PH12015502019A1 (enExample)
SG (2) SG10201707590XA (enExample)
TN (1) TN2015000390A1 (enExample)
TW (1) TW201521744A (enExample)
UY (1) UY35441A (enExample)
WO (1) WO2014150873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
MX2020002048A (es) * 2017-08-31 2020-09-21 Cytosorbents Corp Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085377A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for lowering serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
EP1753861A4 (en) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
ES2549513T3 (es) * 2010-02-24 2015-10-28 Relypsa, Inc. Polivinilamina, polialilamina y polietilenimina reticuladas para uso como secuestradores de ácidos biliares

Also Published As

Publication number Publication date
JP2022037143A (ja) 2022-03-08
IL241406A0 (en) 2015-11-30
CA2906501A1 (en) 2014-09-25
PH12015502019A1 (en) 2016-01-11
HK1220607A1 (zh) 2017-05-12
BR112015023404A8 (pt) 2019-12-03
WO2014150873A1 (en) 2014-09-25
EA201591733A1 (ru) 2016-01-29
JP2020055850A (ja) 2020-04-09
AU2014235500A1 (en) 2015-11-05
EP2968403A1 (en) 2016-01-20
US20160024233A1 (en) 2016-01-28
AU2019201259A1 (en) 2019-03-14
UY35441A (es) 2014-10-31
KR20150130492A (ko) 2015-11-23
SG11201506413PA (en) 2015-09-29
MA38487A1 (fr) 2017-12-29
PE20151766A1 (es) 2015-12-11
CR20150545A (es) 2015-12-01
MX2015012843A (es) 2016-08-08
BR112015023404A2 (pt) 2017-07-18
US20180265613A1 (en) 2018-09-20
SG10201707590XA (en) 2017-11-29
TW201521744A (zh) 2015-06-16
DOP2015000221A (es) 2015-12-15
CL2015002624A1 (es) 2016-03-11
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
JP2018135365A (ja) 2018-08-30
JP2016512830A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
AR094668A1 (es) Amidas como moduladores de canales de sodio
WO2016134301A3 (en) Neuroactive steroids, compositions, and uses thereof
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
JP2015537020A5 (enExample)
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
JP2013521312A5 (enExample)
JP2013032389A5 (enExample)
JP2014508753A5 (enExample)
RU2013142448A (ru) Новые сульфонаминохинолиновые антагонисты гепсидина
JP2014534200A5 (enExample)
PH12015500465A1 (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
AR086522A1 (es) Inhibidores heterociclicos de autotaxina y usos de los mismos
JP2014528480A5 (enExample)
AR098522A1 (es) Compuesto de triazolo-piridina
EA201591027A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
JP2014531441A5 (enExample)
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
JP2017536416A5 (enExample)
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
RU2015144224A (ru) Амин-функциональные полиамиды

Legal Events

Date Code Title Description
FB Suspension of granting procedure